SI2773638T1 - Spojine heteroaril piridona in aza-priridona kot zaviralci btk-aktivnosti - Google Patents

Spojine heteroaril piridona in aza-priridona kot zaviralci btk-aktivnosti

Info

Publication number
SI2773638T1
SI2773638T1 SI201230367T SI201230367T SI2773638T1 SI 2773638 T1 SI2773638 T1 SI 2773638T1 SI 201230367 T SI201230367 T SI 201230367T SI 201230367 T SI201230367 T SI 201230367T SI 2773638 T1 SI2773638 T1 SI 2773638T1
Authority
SI
Slovenia
Prior art keywords
pyridone
aza
inhibitors
heteroaryl
btk activity
Prior art date
Application number
SI201230367T
Other languages
English (en)
Slovenian (sl)
Inventor
James John Crawford
Daniel Fred Ortwine
Binqing Wei
Wendy B. Young
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI2773638T1 publication Critical patent/SI2773638T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI201230367T 2011-11-03 2012-11-02 Spojine heteroaril piridona in aza-priridona kot zaviralci btk-aktivnosti SI2773638T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555393P 2011-11-03 2011-11-03
PCT/US2012/063194 WO2013067274A1 (en) 2011-11-03 2012-11-02 Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
EP12783837.3A EP2773638B1 (en) 2011-11-03 2012-11-02 Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Publications (1)

Publication Number Publication Date
SI2773638T1 true SI2773638T1 (sl) 2015-12-31

Family

ID=47146779

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201230367T SI2773638T1 (sl) 2011-11-03 2012-11-02 Spojine heteroaril piridona in aza-priridona kot zaviralci btk-aktivnosti
SI201231643T SI3002284T1 (sl) 2011-11-03 2012-11-02 Spojini heteroaril piridon in aza-piridon kot inhibitorja dejavnosti BTK

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201231643T SI3002284T1 (sl) 2011-11-03 2012-11-02 Spojini heteroaril piridon in aza-piridon kot inhibitorja dejavnosti BTK

Country Status (34)

Country Link
US (11) US8716274B2 (OSRAM)
EP (5) EP3521288B1 (OSRAM)
JP (5) JP5976827B2 (OSRAM)
KR (2) KR20160003328A (OSRAM)
CN (2) CN107011348B (OSRAM)
AR (2) AR088641A1 (OSRAM)
AU (5) AU2012332365B2 (OSRAM)
CA (1) CA2853975C (OSRAM)
CL (1) CL2014001103A1 (OSRAM)
CO (1) CO6950472A2 (OSRAM)
CR (1) CR20140194A (OSRAM)
CY (1) CY1117097T1 (OSRAM)
DK (2) DK2773638T3 (OSRAM)
EA (1) EA023263B1 (OSRAM)
ES (3) ES2898938T3 (OSRAM)
HR (2) HRP20151442T1 (OSRAM)
HU (2) HUE028019T2 (OSRAM)
IL (1) IL232060A (OSRAM)
IN (1) IN2014CN03250A (OSRAM)
LT (1) LT3002284T (OSRAM)
MA (1) MA35819B1 (OSRAM)
MX (2) MX2014005331A (OSRAM)
PE (1) PE20141586A1 (OSRAM)
PH (1) PH12014500936A1 (OSRAM)
PL (3) PL3002284T3 (OSRAM)
PT (2) PT2773638E (OSRAM)
RS (2) RS54505B1 (OSRAM)
SG (1) SG11201401992YA (OSRAM)
SI (2) SI2773638T1 (OSRAM)
TR (1) TR201909849T4 (OSRAM)
TW (4) TWI609868B (OSRAM)
UA (1) UA111756C2 (OSRAM)
WO (1) WO2013067274A1 (OSRAM)
ZA (1) ZA201804727B (OSRAM)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101716011B1 (ko) * 2011-11-03 2017-03-13 에프. 호프만-라 로슈 아게 Btk 활성의 억제제인 알킬화된 피페라진 화합물
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
RU2016101548A (ru) * 2013-07-03 2017-08-08 Ф. Хоффманн-Ля Рош Аг Соединения амидов гетероарилпиридона и азапиридона
WO2015050703A1 (en) * 2013-10-04 2015-04-09 Yi Chen Inhibitors of bruton's tyrosine kinase
RU2646758C2 (ru) * 2013-12-05 2018-03-07 Ф. Хоффманн-Ля Рош Аг Гетероарил пиридоны и азапиридоны с электрофильной функциональностью
JP6507234B2 (ja) * 2014-10-02 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼ（ｂｔｋ）によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物
CN111747956A (zh) * 2014-10-27 2020-10-09 豪夫迈·罗氏有限公司 制备三环内酰胺化合物的方法
CN106188063A (zh) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
AU2016315360B2 (en) 2015-09-02 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
CA3002560A1 (en) 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
US20200270265A1 (en) * 2016-02-19 2020-08-27 Novartis Ag Tetracyclic pyridone compounds as antivirals
KR20200118507A (ko) * 2016-02-29 2020-10-15 에프. 호프만-라 로슈 아게 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물
CN108473510B (zh) * 2016-04-28 2021-10-29 豪夫迈·罗氏有限公司 制备2-吡唑并[1,5-a]吡嗪-2-基吡啶并[1,2-a]嘧啶-4-酮的方法
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
JP2020510624A (ja) 2016-12-12 2020-04-09 マルチビア インコーポレイテッド がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
SG10201913918UA (en) * 2016-12-15 2020-03-30 Hoffmann La Roche Process for preparing btk inhibitors
ES2917377T3 (es) 2016-12-22 2022-07-08 Betta Pharmaceuticals Co Ltd Derivados de benzimidazol, procedimientos de preparación y utilizaciones de los mismos
WO2018175863A1 (en) 2017-03-24 2018-09-27 Genentech, Inc. Methods of treating autoimmune and inflammatory diseases
CN107445981B (zh) * 2017-08-25 2018-06-22 牡丹江医学院 一种用于防治宫颈炎的活性化合物
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
JP7100125B2 (ja) 2017-10-27 2022-07-12 フレゼニウス・カビ・オンコロジー・リミテッド リボシクリブおよびその塩の改善された調製のためのプロセス
US11100492B2 (en) * 2018-02-19 2021-08-24 Peter Garrett General purpose re-loadable card aggregation implementation
US11702427B2 (en) 2018-03-12 2023-07-18 Arbutus Biopharma Corporation Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
EP3789040A4 (en) 2018-04-27 2022-03-09 ONO Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
BR112021000964A2 (pt) 2018-07-25 2021-04-20 Novartis Ag inibidores do inflamassoma de nlrp3
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020043321A1 (en) 2018-08-31 2020-03-05 Stichting Katholieke Universiteit Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof
BR122023024103A2 (pt) 2018-10-15 2024-02-20 Nurix Therapeutics, Inc. Compostos bifuncionais para degradação de btk por meio da via de proteossoma de ubiquitina, composição farmacêutica compreendendo os mesmos, e seus usos
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
TW202033523A (zh) * 2019-01-17 2020-09-16 美商愛彼特生物製藥股份有限公司 經取代的多環羧酸、其類似物及使用其之方法
WO2020154252A1 (en) 2019-01-22 2020-07-30 Genentech, Inc. Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
US20220135569A1 (en) 2019-02-25 2022-05-05 Newave Pharmaceutical Inc. Inhibitor of btk and mutants thereof
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
MX2021012285A (es) 2019-04-09 2021-12-15 Nurix Therapeutics Inc Compuestos de piperidina 3-sustituidos para inhibicion del protooncogen-b de linfoma de linea b de casitas (cbl-b) y uso de un inhibidor de cbl-b en combinacion con una vacuna contra el cancer y/o con un virus oncolitico.
WO2020236654A1 (en) 2019-05-17 2020-11-26 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11401267B2 (en) 2019-06-26 2022-08-02 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
US20220363689A1 (en) 2019-10-05 2022-11-17 Newave Pharmaceutical Inc. Inhibitor of btk and mutants thereof
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021091575A1 (en) * 2019-11-08 2021-05-14 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
EP4570320A3 (en) 2019-12-04 2025-08-27 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
MX2022010219A (es) * 2020-02-20 2022-09-19 Hutchison Medipharma Ltd Compuestos heterociclicos de heteroarilo y usos de los mismos.
KR20220148826A (ko) 2020-02-28 2022-11-07 제넨테크, 인크. 브루톤 티로신 키나아제의 저해제를 이용하여 원발성 진행형 다발성 경화증을 치료하는 방법
AU2021249129A1 (en) 2020-04-03 2022-10-20 F. Hoffmann-La Roche Ag Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase
CN115715291B (zh) * 2020-06-18 2025-04-29 上海华汇拓医药科技有限公司 布鲁顿酪氨酸激酶抑制剂及其制备方法
WO2022029068A1 (en) * 2020-08-04 2022-02-10 F. Hoffmann-La Roche Ag Pyridinone compounds for the treatment of autoimmune disease
AU2021325431B2 (en) 2020-08-14 2024-01-18 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
US20230346779A1 (en) * 2020-08-14 2023-11-02 Newave Pharmaceutical Inc. Dosage form compositions comprising an inhibitor of btk and mutants thereof
CN116568687B (zh) 2020-09-21 2025-09-02 和记黄埔医药（上海）有限公司 杂芳基杂环化合物及其用途
WO2022094172A2 (en) 2020-10-30 2022-05-05 Newave Pharmaceutical Inc. Inhibitors of btk
EP4263552A1 (en) 2020-12-20 2023-10-25 Guangzhou Lupeng Pharmaceutical Company Ltd. Btk degrader
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2022217123A2 (en) 2021-04-08 2022-10-13 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds
MX2023012960A (es) 2021-05-05 2023-11-16 Hoffmann La Roche Proceso para preparar inhibidores de btk.
CN113603685A (zh) * 2021-07-23 2021-11-05 都创(上海)医药开发有限公司 Fenebrutinib化合物的晶型及其制备方法和用途
US12377106B2 (en) 2021-10-26 2025-08-05 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors
WO2023137225A1 (en) * 2022-01-17 2023-07-20 Newave Pharmaceutical Inc. Btk degrader
TW202346276A (zh) 2022-01-27 2023-12-01 日商田邊三菱製藥股份有限公司 新穎之ｂ０ａｔ１抑制劑
US20250154155A1 (en) 2022-01-28 2025-05-15 Hutchmed Limited Synthetic method of 7,8-dihydro-2h-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6h)-one compounds
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
AR132314A1 (es) 2023-04-06 2025-06-11 Mitsubishi Tanabe Pharma Corp Nuevo inhibidor de b0at1
WO2024238524A1 (en) 2023-05-16 2024-11-21 Genentech, Inc. Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2025031344A1 (zh) * 2023-08-07 2025-02-13 广州麓鹏制药有限公司 一种丙烯酰胺类化合物的晶型vi及其制备方法和用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
BR0211073A (pt) 2001-07-12 2004-12-14 Avecia Ltd Sistema de catalisador, e, processos para a preparação de um catalisador microencapsulado, de bifenilas opcionalmente substituìdas, de alcenos opcionalmente substituìdos, de um produto hidrogenado e de dióis
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
EA200700225A1 (ru) 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. Аналоги тетрапептида
SG159549A1 (en) 2004-11-10 2010-03-30 Cgi Pharmaceuticals Inc Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
BRPI0608252A2 (pt) 2005-03-10 2010-04-06 Cgi Pharmaceuticals Inc entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
AR063706A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PT2201840E (pt) * 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CA2701275C (en) * 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Kinase inhibitors
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CA2710462C (en) * 2008-02-05 2015-11-24 F. Hoffmann-La Roche Ag Pyridinones and pyridazinones
AU2009244291B2 (en) 2008-05-06 2014-02-13 Genentech, Inc. Substituted amides, method of making, and use as Btk inhibitors
CN103709148B (zh) * 2008-06-24 2015-10-21 霍夫曼-拉罗奇有限公司 取代的吡啶-2-酮和哒嗪-3-酮
JP5490789B2 (ja) 2008-07-02 2014-05-14 エフ．ホフマン−ラ ロシュ アーゲー キナーゼ阻害剤としての新規なフェニルピラジノン
CA2636807A1 (en) 2008-07-04 2010-01-04 Steven Splinter Methods for obtaining cyclopamine
ES2552681T3 (es) 2008-07-15 2015-12-01 F. Hoffmann-La Roche Ag Nuevas fenil-imidazopiridinas y piridazinas
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
ES2513915T3 (es) * 2009-04-24 2014-10-27 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
EP2424368B1 (en) * 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
PL2473049T3 (pl) * 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
ES2573716T3 (es) * 2010-05-07 2016-06-09 Gilead Connecticut, Inc. Compuestos de piridona y aza-piridona y métodos de utilización
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
CN103189369B (zh) 2010-09-01 2016-08-24 吉利德康涅狄格有限公司 吡啶酮/吡嗪酮、其制备方法及使用方法
EP2611798B1 (en) 2010-09-01 2015-04-08 Gilead Connecticut, Inc. Pyridazinones, method of making, and method of use thereof
BR112013029620A2 (pt) 2011-05-17 2016-09-06 Hoffmann La Roche inibidores de tirosina quinase de bruton
AU2012296888A1 (en) 2011-08-17 2014-01-23 F. Hoffmann-La Roche Ag Inhibitors of Bruton's Tyrosine Kinase
KR101716011B1 (ko) * 2011-11-03 2017-03-13 에프. 호프만-라 로슈 아게 Btk 활성의 억제제인 알킬화된 피페라진 화합물
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
KR101696525B1 (ko) * 2011-11-03 2017-01-13 에프. 호프만-라 로슈 아게 Btk 활성 억제제로서의 8-플루오로프탈라진-1(2h)-온 화합물
RU2016101548A (ru) * 2013-07-03 2017-08-08 Ф. Хоффманн-Ля Рош Аг Соединения амидов гетероарилпиридона и азапиридона
RU2646758C2 (ru) * 2013-12-05 2018-03-07 Ф. Хоффманн-Ля Рош Аг Гетероарил пиридоны и азапиридоны с электрофильной функциональностью
KR20200118507A (ko) * 2016-02-29 2020-10-15 에프. 호프만-라 로슈 아게 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물

Also Published As

Publication number Publication date
TW202124384A (zh) 2021-07-01
ES2555168T3 (es) 2015-12-29
KR20140096097A (ko) 2014-08-04
KR20160003328A (ko) 2016-01-08
KR101659193B1 (ko) 2016-09-22
EP3002284A1 (en) 2016-04-06
CN107011348B (zh) 2020-01-10
LT3002284T (lt) 2019-08-12
CA2853975C (en) 2020-02-25
AR117501A2 (es) 2021-08-11
EP4019508A1 (en) 2022-06-29
US9782405B2 (en) 2017-10-10
BR112014010459A2 (pt) 2017-04-18
JP2019108342A (ja) 2019-07-04
AR088641A1 (es) 2014-06-25
EP3521288A1 (en) 2019-08-07
EP3521288B1 (en) 2021-09-08
US20230279012A1 (en) 2023-09-07
JP2016028046A (ja) 2016-02-25
MA35819B1 (fr) 2014-12-01
ZA201804727B (en) 2023-03-29
CN104125959B (zh) 2017-05-03
TR201909849T4 (tr) 2019-07-22
TWI652270B (zh) 2019-03-01
MX361807B (es) 2018-12-17
US20180071286A1 (en) 2018-03-15
RS54505B1 (sr) 2016-06-30
AU2020202707A1 (en) 2020-05-14
US20140378432A1 (en) 2014-12-25
JP2014532762A (ja) 2014-12-08
US8716274B2 (en) 2014-05-06
HRP20151442T1 (hr) 2016-01-29
PT2773638E (pt) 2016-01-12
US20140194408A1 (en) 2014-07-10
EP2773638A1 (en) 2014-09-10
HUE028019T2 (en) 2016-11-28
AU2012332365B2 (en) 2016-09-15
US10045983B2 (en) 2018-08-14
AU2019216728A1 (en) 2019-09-05
CO6950472A2 (es) 2014-05-20
DK3002284T3 (da) 2019-07-29
CN104125959A (zh) 2014-10-29
PH12014500936A1 (en) 2014-06-09
WO2013067274A1 (en) 2013-05-10
EP3002284B1 (en) 2019-05-22
PL3521288T3 (pl) 2021-12-27
MX2014005331A (es) 2014-05-28
EA201490858A1 (ru) 2014-08-29
US20190194203A1 (en) 2019-06-27
EP2773638B1 (en) 2015-10-07
PE20141586A1 (es) 2014-10-25
AU2012332365A1 (en) 2014-05-01
CY1117097T1 (el) 2017-04-05
TWI701250B (zh) 2020-08-11
JP2020183397A (ja) 2020-11-12
AU2018201557A1 (en) 2018-03-22
CL2014001103A1 (es) 2014-10-03
HUE044959T2 (hu) 2019-12-30
SG11201401992YA (en) 2014-05-29
AU2016273930A1 (en) 2017-01-12
IL232060A (en) 2016-02-29
CN107011348A (zh) 2017-08-04
US8921353B2 (en) 2014-12-30
US9238655B2 (en) 2016-01-19
PT3002284T (pt) 2019-07-17
RS59016B1 (sr) 2019-08-30
HK1201265A1 (en) 2015-08-28
EP4050012A1 (en) 2022-08-31
JP2018080193A (ja) 2018-05-24
JP5976827B2 (ja) 2016-08-24
TW201906845A (zh) 2019-02-16
US20160228432A1 (en) 2016-08-11
DK2773638T3 (en) 2015-10-19
TWI609868B (zh) 2018-01-01
US20210079002A1 (en) 2021-03-18
ES2898938T3 (es) 2022-03-09
SI3002284T1 (sl) 2019-08-30
UA111756C2 (uk) 2016-06-10
PL3002284T3 (pl) 2019-11-29
AU2016273930B2 (en) 2018-03-08
ES2738329T3 (es) 2020-01-22
TW201326175A (zh) 2013-07-01
PL2773638T3 (pl) 2016-03-31
US20200062769A1 (en) 2020-02-27
EA023263B1 (ru) 2016-05-31
IL232060A0 (en) 2014-05-28
CR20140194A (es) 2014-06-03
AU2020202707B2 (en) 2021-09-02
NZ624021A (en) 2016-09-30
TW201741315A (zh) 2017-12-01
US20240270747A1 (en) 2024-08-15
CA2853975A1 (en) 2013-05-10
JP6571215B2 (ja) 2019-09-04
USRE48239E1 (en) 2020-10-06
AU2019216728B2 (en) 2020-04-09
HRP20191307T1 (hr) 2019-10-18
US20130116235A1 (en) 2013-05-09
IN2014CN03250A (OSRAM) 2015-07-03
AU2018201557B2 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
ZA201804727B (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
IL266168A (en) Heteroaryl compounds and methods of their use
ZA201209205B (en) Pyridone and aza-pyridone compounds and methods of use
IL238409A (en) Pde4 antitumor inhibitors
ZA201307632B (en) Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
ZA201403158B (en) Alkylated piperazine compounds as inhibitors of btk activity
ZA201303793B (en) Substituted quinoline compounds and methods of use
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2758387A4 (en) Pyridine compounds as kinase inhibitors
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
ZA201408856B (en) Heteroaryl compounds and methods of use thereof
IL232170A0 (en) Heterocyclic carboxamides are useful as phosphodiesterase type 10a inhibitors
TH1401002406B (th) สารประกอบเฮทเทอโรเอริล ไพริโดน และ อะซา-ไพริโดนในรูปสารยับยั้งของ btk แอคตีวิตี้
HK1191650A (en) Picolinamide inhibitors of kinases